Claims for Patent: 9,820,798

Summary for Patent: 9,820,798

Title:	System and method for providing targeted ablation of parathyroidal tissue
Abstract:	Targeted ablation of parathyroidal tissue is provided through hyperthermia adjuvant therapy. An in situ localization of parathyroidal tissue is obtained. A temperature-sensitive adjuvant is instilled into the parathyroidal tissue. Hyperthermia is therapeutically induced within the parathyroidal tissue. Heat-inducing energy is targeted into the parathyroidal tissue, which selectively includes the temperature-sensitive adjuvant. Application of the heat-inducing energy to the parathyroidal tissue is continued over a therapeutic range. In a further embodiment, the targeted ablation of the parathyroidal tissue is provided through hypothermia adjuvant therapy with the targeted use of cold-inducing energy.
Inventor(s):	Schwartz; Alan N. (Edmonds, WA)
Assignee:
Application Number:	14/639,991
Patent Claims:	1. A method for providing targeted ablation of parathyroidal tissue of a parathyroid gland, comprising the steps of: determining a quantity of an activator substance that is less than a cytotoxic ablation quantity threshold, wherein when the quantity of the activator substance is more than the cytotoxic ablation quantity threshold, the quantity of the activator substance is capable of transforming the parathyroid gland from overproduction of parathyroid hormone to non-overproduction of the parathyroid hormone and wherein when the quantity of the activator substance is less than the cytotoxic ablation quantity threshold, the quantity of the activator substance is not capable of transforming the parathyroid gland from overproduction of parathyroid hormone to non-overproduction of the parathyroid hormone; selecting a quantity of energy that is less than a cytotoxic ablation energy threshold, wherein when the quantity of the energy is more than the cytotoxic ablation energy threshold, the quantity of the energy is capable of transforming the parathyroid gland from overproduction of the parathyroid hormone to non-overproduction of the parathyroid hormone and wherein when the quantity of the energy is less than the cytotoxic ablation energy threshold, the quantity of the energy is not capable of transforming the parathyroid gland from overproduction of parathyroid hormone to non-overproduction of the parathyroid hormone; placing the quantity of the activator substance that is not activated into the parathyroidal tissue; therapeutically cytotoxically ablating the parathyoidal tissue by applying the quantity of the energy to the quantity of the activator substance within the parathyroidal tissue to activate the quantity of the activator substance, wherein the quantities of the energy and the activator substance, together, transform the parathyroid gland from overproduction of the parathyroid hormone to non-overproduction of the parathyroid hormone, wherein placing the quantity of the activator substance within the parathyroidal tissue and applying the quantity of the energy to the quantity of the activator substance is performed in a manner that maintains non-parathyroidal functions, does not cytotoxically ablate non-parathyroid local tissue, and is non-lethal to the living human. 2. The method in accordance with claim 1, further comprising the step of: monitoring the ablating of the parathyroidal tissue during transformation of the parathyroid gland from overproduction of the parathyroid hormone to non-overproduction of the parathyroid hormone after the quantity of energy is applied. 3. The method in accordance with claim 1, further comprising the step of: cauterizing blood vessels in the parathyroidal tissue after the quantity of the activator substance is placed and the quantity of the energy is applied. 4. The method in accordance with claim 1, wherein the quantity of the activator substance can be activated by a second energy, further comprising the steps of: selecting a quantity of the second energy that is less than the cytotoxic ablation energy threshold, wherein when the quantity of the second energy is more than the cytotoxic ablation energy threshold, the quantity of the second energy is capable of transforming the parathyroid gland from overproduction of the parathyroid hormone to non-overproduction of the parathyroid hormone and wherein when the quantity of the second energy is less than the cytotoxic ablation energy threshold, the quantity of the second energy is not capable of transforming the parathyroid gland from overproduction of parathyroid hormone to non-overproduction of the parathyroid hormone; applying the quantity of the second energy to the quantity of the activator substance within the parathyroidal tissue in conjunction with the quantity of the energy. 5. The method in accordance with claim 1, further comprising the steps of: determining a quantity of a second activator substance that is less than the cytotoxic ablation quantity threshold, wherein when the quantity of the second activator substance is more than the cytotoxic ablation quantity threshold, the quantity of the second activator substance is capable of transforming the parathyroid gland from overproduction of parathyroid hormone to non-overproduction of the parathyroid hormone and wherein when the quantity of the second activator substance is less than the cytotoxic ablation quantity threshold, the quantity of the second activator substance is not capable of transforming the parathyroid gland from overproduction of parathyroid hormone to non-overproduction of the parathyroid hormone; applying the quantity of the energy to the quantity of the second activator substance within the parathyroid tissue in conjunction with the quantity of the activator substance. 6. The method in accordance with claim 1, wherein the activator substance comprises nano objects. 7. The method in accordance with claim 1, wherein the energy is selected from the group comprising electromagnetic, kinetic, thermal, mechanical, oscillation, ultrasound, magnetic resonance, radio frequency, magnetic, laser, vibrational, thermal, cryotherapy, high intensity focused ultrasound, acoustic, optical-acoustic ultrasound, microwave, radioactive, x-ray, irreversible electroporation, electric current, electro cautery, chemical, electro chemical, mechanical chemical, ultraviolet light, infrared light, and visible light. 8. The method in accordance with claim 1, wherein applying the quantity of the energy comprises using one or more of a plurality of energy modalities, types, and intensities. 9. The method in accordance with claim 1, wherein placing the quantity of the activator substance comprises at least one of the steps of: placing the quantity of the activator substance into the parathyroidal tissue through an intravascular modality; placing the quantity of the activator substance into the parathyroidal tissue through a transcutaneous modality; placing the quantity of the activator substance into the parathyroidal tissue through a surgical modality; or placing the quantity of the activator substance into the parathyroidal tissue through a percutaneous modality. 10. The method in accordance with claim 1, wherein applying the quantity of the energy comprises at least one of the steps of: applying the quantity of the energy to the quantity of the activator substance through an intravascular modality; applying the quantity of the energy to the quantity of the activator substance through a transcutaneous modality; applying the quantity of the energy to the quantity of the activator substance through a surgical modality; or applying the quantity of the energy to the quantity of the activator substance through a percutaneous modality. 11. The method in accordance with claim 1, wherein placing the quantity of the activator substance comprises at least one of the steps of: placing the quantity of the activator substance into the parathyroidal tissue by exposing the parathyroidal tissue to a modality coated or insulated with the quantity of the activator substance; placing the quantity of the activator substance into the parathyroidal tissue by instilling the quantity of the activator substance into the parathyroidal tissue; or placing the quantity of the activator substance into the parathyroidal tissue by depositing the quantity of the activator substance into the parathyroidal tissue following withdrawal of a modality to which the quantity of the activator substance was distally affixed. 12. The method in accordance with claim 1, further comprising the step of: protecting the non-parathyroid local tissue located near the parathyroid gland by placing an insulating material into the non-parathyroid local tissue. 13. The method in accordance with claim 6, wherein the nano objects comprise inorganic compounds. 14. The method in accordance with claim 13, wherein the inorganic compounds comprise carbon, silicon, metals, precious metals, and ferromagnetic metals. 15. The method in accordance with claim 6, wherein the nano objects comprise organic compounds. 16. The method in accordance with claim 15, wherein the organic compounds comprise carbon. 17. The method in accordance with claim 1, wherein determining the quantity of the activator substance comprises: choosing the quantity of the activator substance so as to avoid cytotoxic ablation of the non-parathyroid local tissue located near the parathyroid gland, maintain the non-parathyroid functions, and to be non-lethal to the living human. 18. The method in accordance with claim 1, wherein the activator substance comprises a gel, slurry, or plasma. 19. A method for providing targeted hyperthermic cytotoxic ablation of parathyroidal tissue of a parathyroid gland, comprising the steps of: determining a quantity of an activator substance that is less than a cytotoxic ablation quantity threshold, wherein when the quantity of the activator substance is more than the cytotoxic ablation quantity threshold, the quantity of the activator substance is capable of transforming the parathyroid gland from overproduction of parathyroid hormone to non-overproduction of the parathyroid hormone and wherein when the quantity of the activator substance is less than the cytotoxic ablation quantity threshold, the quantity of the activator substance is not capable of transforming the parathyroid gland from overproduction of parathyroid hormone to non-overproduction of the parathyroid hormone; selecting a quantity of energy that is less than a cytotoxic ablation energy threshold, wherein when the quantity of the energy is more than the cytotoxic ablation energy threshold, the quantity of the energy is capable of transforming the parathyroid gland from overproduction of the parathyroid hormone to non-overproduction of the parathyroid hormone and wherein when the quantity of the energy is less than the cytotoxic ablation quantity threshold, the quantity of the energy is not capable of transforming the parathyroid gland from overproduction of parathyroid hormone to non-overproduction of the parathyroid hormone; placing the quantity of the activator substance that is not activated into the parathyroidal tissue; therapeutically cytotoxically ablating the parathyoidal tissue through a hyperthermic reaction by applying the quantity of the energy to the quantity of the activator substance within the parathyroidal tissue to activate the quantity of the activator substance, wherein the quantities of the energy and the activator substance, together, transform the parathyroid gland from overproduction of the parathyroid hormone to non-overproduction of the parathyroid hormone, wherein placing the quantity of the activator substance within the parathyroidal tissue and applying the quantity of the energy to the quantity of the activator substance is performed in a manner that maintains non-parathyroidal functions, does not cytotoxically ablate non-parathyroid local tissue, and is non-lethal to the living human. 20. A method for providing targeted hypothermic cytotoxic ablation of parathyroidal tissue of a parathyroid gland, comprising the steps of: determining a quantity of an activator substance that is less than a cytotoxic ablation quantity threshold, wherein when the quantity of the activator substance is more than the cytotoxic ablation quantity threshold, the quantity of the activator substance is capable of transforming the parathyroid gland from overproduction of parathyroid hormone to non-overproduction of the parathyroid hormone and wherein when the quantity of the activator substance is less than the cytotoxic ablation quantity threshold, the quantity of the activator substance is not capable of transforming the parathyroid gland from overproduction of parathyroid hormone to non-overproduction of the parathyroid hormone; selecting a quantity of energy that is less than a cytotoxic ablation energy threshold, wherein when the quantity of the energy is more than the cytotoxic ablation energy threshold, the quantity of the energy is capable of transforming the parathyroid gland from overproduction of the parathyroid hormone to non-overproduction of the parathyroid hormone and wherein when the quantity of the energy is less than the cytotoxic ablation quantity threshold, the quantity of the energy is not capable of transforming the parathyroid gland from overproduction of parathyroid hormone to non-overproduction of the parathyroid hormone; placing the quantity of the activator substance that is not activated into the parathyroidal tissue; therapeutically cytotoxically ablating the parathyoidal tissue through a hypothermic reaction by applying the quantity of the energy to the quantity of the activator substance within the parathyroidal tissue to activate the quantity of the activator substance, wherein the quantities of the energy and the activator substance, together, transform the parathyroid gland from overproduction of the parathyroid hormone to non-overproduction of the parathyroid hormone, wherein placing the quantity of the activator substance within the parathyroidal tissue and applying the quantity of the energy to the quantity of the activator substance is performed in a manner that maintains non-parathyroidal functions, does not cytotoxically ablate non-parathyroid local tissue, and is non-lethal to the living human.

Details for Patent 9,820,798

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2031-09-23